Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AOMS1
MCID: ABD014
MIFTS: 58

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

About this section

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 58 12 15
Metabolic Syndrome X 58 12 77 30 56 74
Metabolic Syndrome 45 41 17 64
Abdominal Obesity Metabolic Syndrome 74
Dysmetabolic Syndrome X 12
Aoms1 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:14221
OMIM 58 605552
ICD9CM 36 277.7
MeSH 45 D024821
NCIt 51 C84442
ICD10 34 E88.81
MedGen 43 C4552048
Sources

Summaries for Abdominal Obesity-Metabolic Syndrome 1

About this section
OMIM : 58 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and nonalcoholic fatty liver disease, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Simvastatin and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and heart, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 64 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease.In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries.Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 77 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Sources

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

About this section

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 528)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.1 INS LEP SLC2A4
2 nonalcoholic fatty liver disease 30.6 INS LEP
3 liver disease 30.5 INS LEP MEG3
4 nonalcoholic steatohepatitis 30.3 INS LEP
5 sleep apnea 30.2 INS LEP
6 fatty liver disease, nonalcoholic 1 30.1 INS LEP
7 apnea, obstructive sleep 30.1 INS LEP
8 lipid metabolism disorder 30.0 INS LEP SERPINE1
9 arteries, anomalies of 30.0 INS LEP SERPINE1
10 glucose intolerance 29.9 INS LEP SLC2A4
11 hyperandrogenism 29.9 HSD11B1 INS
12 gestational diabetes 29.8 INS LEP SLC2A4
13 acanthosis nigricans 29.7 INS LEP
14 atherosclerosis susceptibility 29.7 INS SERPINE1
15 morbid obesity 29.7 INS LEP
16 cerebrovascular disease 29.6 INS MEG3 SERPINE1
17 microvascular complications of diabetes 5 29.6 INS SERPINE1
18 hypertension, essential 29.5 INS LEP SERPINE1
19 hyperinsulinism 29.5 INS LEP SERPINE1
20 pancreas disease 29.5 INS LEP
21 familial hyperlipidemia 29.3 INS SERPINE1
22 familial partial lipodystrophy 29.2 INS LEP
23 diabetic neuropathy 29.2 INS LEP
24 insulin-like growth factor i 29.1 INS LEP
25 alstrom syndrome 29.0 INS LEP
26 body mass index quantitative trait locus 11 28.9 HSD11B1 INS LEP SERPINE1 SLC2A4
27 inherited metabolic disorder 28.9 INS LEP
28 diabetes mellitus, noninsulin-dependent 28.7 HSD11B1 INS LEP SERPINE1 SLC2A4
29 diabetes mellitus 28.3 INS LEP MEG3 SERPINE1 SLC2A4
30 glucose metabolism disease 28.3 INS LEP SERPINE1 SLC2A4
31 overnutrition 28.1 HSD11B1 INS LEP SERPINE1 SLC2A4
32 abdominal obesity-metabolic syndrome 3 12.3
33 fatty liver disease 11.3
34 polycystic ovary syndrome 11.2
35 gracile syndrome 11.2
36 gallbladder disease 1 11.0
37 smith-lemli-opitz syndrome 10.7
38 diabetes mellitus, noninsulin-dependent, 1 10.7
39 glaucoma, normal tension 10.7
40 diabetes mellitus, noninsulin-dependent, 5 10.7
41 peroneal nerve paralysis 10.7
42 47, xxy 10.7
43 coronary artery anomaly 10.4
44 impotence 10.3
45 schizophrenia 10.3
46 psoriasis 10.3
47 body mass index quantitative trait locus 10 10.3
48 body mass index quantitative trait locus 14 10.3
49 body mass index quantitative trait locus 18 10.3
50 body mass index quantitative trait locus 19 10.3

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1
Sources

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

About this section

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

33
# Description HPO Frequency HPO Source Accession
1 hypertension 33 HP:0000822
2 abdominal obesity 33 HP:0012743

Symptoms via clinical synopsis from OMIM:

58
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.55 HSD11B1 INS LEP SERPINE1 SLC2A4
2 cardiovascular system MP:0005385 9.35 HSD11B1 INS LEP SERPINE1 SLC2A4
3 liver/biliary system MP:0005370 9.02 HSD11B1 INS LEP SERPINE1 SLC2A4
Sources

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

About this section

PubMedHealth treatment related to Abdominal Obesity-Metabolic Syndrome 1: 64

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking.If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar.Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 784)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
2
Ezetimibe Approved Phase 4,Phase 3,Not Applicable 163222-33-1 150311
3
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
6
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
9
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
10
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
11
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0, 481-30-1 6013 10204
12
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
14
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
16
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
17
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-93-5 3639
18
Spironolactone Approved Phase 4,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833
19
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
20
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
21
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 130881 158781
22
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 32051
23
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
24
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
25
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
26
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
27
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
28
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
29
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 458-37-7 969516
30
Clozapine Approved Phase 4,Phase 2,Not Applicable 5786-21-0 2818
31
Haloperidol Approved Phase 4,Not Applicable 52-86-8 3559
32
Titanium dioxide Approved Phase 4,Phase 3,Phase 2 13463-67-7
33
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
35
Irbesartan Approved, Investigational Phase 4,Not Applicable 138402-11-6 3749
36
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
37
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
38
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
39
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
40
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
41
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
42
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
43
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
44
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
45
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
46
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
47
Iron Approved, Experimental Phase 4,Not Applicable 7439-89-6, 15438-31-0 23925 27284
48
Allopurinol Approved Phase 4,Phase 2,Not Applicable 315-30-0 2094
49
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable 64-17-5 702
50
Magnesium oxide Approved Phase 4,Phase 2,Phase 3 1309-48-4 14792

Interventional clinical trials:

(show top 50) (show all 2012)
# Name Status NCT ID Phase Drugs
1 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
2 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
4 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
5 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
6 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
7 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
10 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
11 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
12 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
13 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
14 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
15 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
16 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
17 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
18 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
19 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
20 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
21 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
22 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
23 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
24 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
25 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
26 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
27 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
28 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
29 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
30 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
31 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
32 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
33 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
34 Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
35 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
36 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
37 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4 rosuvastatin
38 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome Recruiting NCT02295202 Phase 4
39 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
40 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome Recruiting NCT03440736 Phase 4 Secukinumab
41 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
42 Caduet and TLC Intervention in Metabolic Syndrome Completed NCT03504735 Phase 4 Caduet Pill;Placebo
43 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Active, not recruiting NCT02252406 Phase 4 Ranolazine;Placebo
44 Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome Recruiting NCT03355469 Phase 4 Low Intensity Exercise + Metformin;High Intensity Exercise + Metformin;Low Intensity Exercise + Placebo;High Intensity Exercise + Placebo
45 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome Completed NCT00335699 Phase 4 Rosuvastatin
46 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
47 Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome Recruiting NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
48 A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial - Recruiting NCT02651454 Phase 4 Daesiho-tang;Jowiseungcheung-tang;Placebo
49 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine
50 Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Sources

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

About this section

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 30
Sources

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

About this section

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

42
Liver, Endothelial, Heart, Ovary, Prostate, Bone, Breast
Sources

Publications for Abdominal Obesity-Metabolic Syndrome 1

About this section

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 61)
# Title Authors Year
1
The question of metabolic syndrome X. ( 26631307 )
2015
2
Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X. ( 26413164 )
2015
3
Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. ( 23923606 )
2013
4
Central retinal artery occlusion in a patient with metabolic syndrome x. ( 22737328 )
2010
5
Anaesthetic considerations in metabolic syndrome X. ( 20532086 )
2010
6
Beneficial effects of modified egg* on oxidative stress in F1- generation of metabolic syndrome-X induced Wistar rat. ( 19374165 )
2009
7
Cardiac syndrome X versus metabolic syndrome X. ( 17010457 )
2007
8
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( 17475465 )
2007
9
[The metabolic syndrome X or insulin resistance syndrome]. ( 17304724 )
2007
10
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. ( 16941796 )
2006
11
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. ( 16416266 )
2006
12
Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. ( 16999025 )
2006
13
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 15833894 )
2005
14
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. ( 15734832 )
2005
15
Pathophysiology of metabolic syndrome X and its links to the perinatal period. ( 15925303 )
2005
16
Swiss Medical Weekly Young Investigator's Award 2003: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 15243846 )
2004
17
Metabolic syndrome X: an inflammatory condition? ( 14972097 )
2004
18
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. ( 15470277 )
2004
19
Low-flow vascular remodeling in the metabolic syndrome X. ( 14644764 )
2004
20
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. ( 12697574 )
2003
21
Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions. ( 12781862 )
2003
22
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( 15028595 )
2003
23
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 12756274 )
2003
24
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. ( 12946657 )
2003
25
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. ( 14574352 )
2003
26
Metabolic syndrome X is common in Indians: but, why and how? ( 14719590 )
2003
27
Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. ( 12537988 )
2003
28
Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 12947532 )
2003
29
Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. ( 11856814 )
2002
30
The metabolic syndrome X and peripheral cortisol synthesis. ( 12397528 )
2002
31
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. ( 12512799 )
2002
32
Is metabolic syndrome X an inflammatory condition? ( 12486208 )
2002
33
Obesity, metabolic syndrome X, and inflammation. ( 11985951 )
2002
34
Metabolic syndrome X--high risk factor for acute myocardial infarction and its complications. ( 12137304 )
2002
35
Metabolic syndrome X is common in South Asians, but why and how? ( 12297221 )
2002
36
Molecular mechanism of vascular disease in metabolic syndrome X. ( 11872360 )
2002
37
Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. ( 11958275 )
2001
38
Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. ( 15573024 )
2001
39
Unravelling metabolic syndrome X. ( 11427370 )
2001
40
Steroid metabolism in metabolic syndrome X. ( 11469814 )
2001
41
Insulin resistance: the metabolic syndrome X ( 10713753 )
2000
42
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. ( 11057441 )
2000
43
Metabolic syndrome X: a review. ( 10863169 )
2000
44
Metabolic syndrome X and fibrinolytic disturbances. ( 10870268 )
2000
45
Liver pathology and the metabolic syndrome X in severe obesity. ( 10323371 )
1999
46
Hypothalamic origin of the metabolic syndrome X. ( 10842670 )
1999
47
The metabolic syndrome X. ( 10842649 )
1999
48
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. ( 10483984 )
1999
49
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. ( 10842660 )
1999
50
Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. ( 10189006 )
1999
Sources

Variations for Abdominal Obesity-Metabolic Syndrome 1

About this section

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome
Sources

Expression for Abdominal Obesity-Metabolic Syndrome 1

About this section
Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.
Sources

Pathways for Abdominal Obesity-Metabolic Syndrome 1

About this section

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.36 INS LEP SLC2A4
2
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 11.96 INS LEP SLC2A4
3
AMPK Enzyme Complex Pathway 65
Show member pathways
 11.57 INS LEP SLC2A4
4
HIF-1 signaling pathway 38
11.54 INS SERPINE1
5
Type II diabetes mellitus 38 1
Show member pathways
 11.51 INS SLC2A4
6
Adipocytokine signaling pathway 38
11.33 LEP SLC2A4
7
HIF-1-alpha transcription factor network 1
11.29 LEP SERPINE1
8
Development_Leptin signaling via PI3K-dependent pathway 23
11.17 LEP SLC2A4
9
Signaling events mediated by PTP1B 1
11.13 INS LEP
10
Arf6 trafficking events 1
11.05 INS SLC2A4
11
Adipogenesis 1
11.04 INS LEP SERPINE1 SLC2A4
12
Insulin-mediated glucose transport 1
10.78 INS SLC2A4
13
Transcription factor regulation in adipogenesis 1
10.6 LEP SLC2A4
14
Cori Cycle 1
10.16 INS SLC2A4
Sources

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

About this section

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.5 INS LEP SERPINE1
2 circadian rhythm GO:0007623 9.37 LEP SERPINE1
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 INS LEP
4 glucose metabolic process GO:0006006 9.16 INS LEP
5 positive regulation of insulin receptor signaling pathway GO:0046628 8.96 INS LEP
6 glucose homeostasis GO:0042593 8.8 INS LEP SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 INS SERPINE1
Sources

Sources for Abdominal Obesity-Metabolic Syndrome 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....